Teva Pharmaceutical Industries (TEVA) Equity Income (2017 - 2026)

Teva Pharmaceutical Industries has disclosed Equity Income across 10 years of filings, most recently posting -$1.0 million for Q1 2026.

• Quarterly Equity Income fell 100.0% year-over-year to -$1.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $13.0 million (up 188.89% YoY) and the FY2025 annual result came in at $15.0 million, up 1400.0% from the prior year.
• Equity Income retreated to -$1.0 million in Q1 2026, from $11.0 million in the prior quarter.
• Over five years, Equity Income peaked at $21.0 million in Q1 2022 and troughed at -$4.0 million in Q1 2024.
• A 5-year average of $2.4 million and a median of $1.0 million in 2022 frame the typical range for Equity Income.
• Biggest YoY gain for Equity Income was 700.0% in 2024; the steepest drop was 900.0% in 2024.
• Tracing TEVA's Equity Income over 5 years: stood at $1.0 million in 2022, then changed by 0.0% to $1.0 million in 2023, then jumped by 200.0% to $3.0 million in 2024, then jumped by 266.67% to $11.0 million in 2025, then slumped by 109.09% to -$1.0 million in 2026.
• Business Quant data shows TEVA's Equity Income at -$1.0 million in Q1 2026, $11.0 million in Q4 2025, and $2.0 million in Q3 2025.